Delivery Order SPE2DB24D2018-SPE2DB24FWTP4

Award Date 7/22/24
Potential Completion Date 7/23/24
Potential Value $2.2K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation, a major pharmaceutical distributor. The $2,321.91 firm-fixed-price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a medication product. The contract has an ultimate completion date of July 31, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued up to $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,672.78 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medication, with an ultimate completion date of May 14, 2025. The contract is not set aside for any specific business category. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC)...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,358.05 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a specialty medication. This contract is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,256.83 firm fixed price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a pharmaceutical product. The contract has an ultimate completion date of October 24, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,608.93 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medical product, with a completion date of March 6, 2025. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,026.84 firm fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML medical products. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,050.12 firm-fixed-price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a specialty medication. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,290.00 firm fixed-price delivery order is for the supply of XYOSTED 75 MG/0.5 ML AUTO-INJ 0.5ML, a specialized pharmaceutical product. The contract has an ultimate completion date of December 18, 2024 and was awarded on December 17, 2024. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor and healthcare solutions provider. The $1,263.91 delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a medication, with a performance period extending through May 9, 2025. The contract is a firm fixed-price delivery order and is not set-aside. AmerisourceBergen Drug Corporation holds a significant $999,999,999.00 Indefinite...
The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML. The contract has a ceiling value of $2,719.51 and runs through October 23, 2024. This delivery order is part of AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and expiring in November 2026. The IDC enables the...
  • SPE2DB24D2018
    Indefinite Delivery Contract
  • SPE2DB24D2018-SPE2DB24FWTP4
    Delivery Order

This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) Troop Support Medical. The $2,242.58 firm-fixed-price delivery order is for the supply of XYOSTED 100 MG/0.5 ML AUTO-INJ 0.5ML, a specialty medication. This award is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for a comprehensive range of medical commodities to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is intended to be completed by July 23, 2024. AmerisourceBergen's extensive supply chain capabilities and status as a leading pharmaceutical distributor in the United States enable the company to effectively fulfill federal government contracts for essential medical products and supplies.

Generated 10/21/24, 9:27 AM